Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V M Factor

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Proceedings of the National Academy of Sciences of the United States of America|June 11, 1996
The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic miceE P Böttinger, V M Factor, M L Tsang, et al.
Cancer Research|September 18, 2001
Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesisY H Im, H T Kim, I Y Kim, et al.
Oncogene|April 19, 2011
Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic responseY-H Lee, A D Judge, D Seo, et al.
Nature Communications|January 10, 2019
The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesisS A Baechler, V M Factor, I Dalla Rosa, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Proceedings of the National Academy of Sciences of the United States of America|June 11, 1996
The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic miceE P Böttinger, V M Factor, M L Tsang, et al.
Cancer Research|September 18, 2001
Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesisY H Im, H T Kim, I Y Kim, et al.
Oncogene|April 19, 2011
Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic responseY-H Lee, A D Judge, D Seo, et al.
Nature Communications|January 10, 2019
The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesisS A Baechler, V M Factor, I Dalla Rosa, et al.
Pageof 4